Table 1 Characteristics and p-value of patients that have PSA after nadir

Number of patients

261

96

-

Mean follow-up ± s.d.

38.7 ± 3.5

15.8 ± 2.4

-

Mean age ± s.d.

74 ± 0.9

75.2 ± 1.7

0.011

Mean time to nadir ± s.d.

10.3 ± 1.3

8.9 ± 1.9

0.001

Mean pretreatment PSA ± s.d.

119.4 ± 39.4

151.5 ± 80.3

0.054

Mean PSA nadir ± s.d.

12.8 ± 11.7

6.6 ± 4.2

0.142

Bone metastasis

Yes

41

15

0.490

No

220

79

Gleason score

0.117

≤ 6

59 (22.6 %)

20 (21.2 %)

7

72 (27.5 %)

21 (22.3 %)

≥ 8

130 (49.8 %)

53 (56.3 %)

ADT type

Leuprin only

154

44

0.012

Zoladex only

36

10

Leuprin → Zoladex

9

6

Zoladex → Leuprin

49

27

Anti-androgen only

13

7